BioCryst Pharmaceuticals BCRX Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's short-term investments?
- BioCryst Pharmaceuticals (BCRX) reported short-term investments of $66.81M in Q1 2026.
- How has BioCryst Pharmaceuticals's short-term investments changed year-over-year?
- BioCryst Pharmaceuticals's short-term investments decreased by 64.8% year-over-year, from $189.9M to $66.81M.
- What is the long-term trend for BioCryst Pharmaceuticals's short-term investments?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's short-term investments has grown at a 45.6% compound annual growth rate (CAGR), from $28.24M to $185.01M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.